Breaking News
Investing Pro 0
🚨 Our Pro Data Reveals the True Winner of Earnings Season Access Data

Healius’ (ASX:HLS) revenue falls by 31% in YTD FY23; here’s why

Stock Markets Nov 28, 2022 14:00
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters Healius’ (ASX:HLS) revenue falls by 31% in YTD FY23;here’s why
 
HLS
-0.63%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
AXHJ
+2.51%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Highlights:

  • Healius reported 31.6% fall in the total revenue to AU$617.5 million during the four months to October 2022.
  • EBITDA during the sated period fell by 64.2% to AU$124.3 million.

Diagnostic services provider Healius Ltd (ASX:HLS) on Monday (28 November 2022) shared a trading update for the four months to October 2022. During the year-to-date financial year 2023 (YTD FY23), the healthcare company posted a 31.6% fall in total revenue and a 64.2% fall in EBITDA. The revenue BAU (business as usual) increased by 5.8% on the prior corresponding period.

Shares of Healius have been buzzing in the red territory since the morning. At 11:40 AM AEDT, the shares were spotted trading 3.26% lower at AU$3.26 per share with a market capitalisation of AU$1.95 billion. Meanwhile, ASX 200 Health Care index was 0.074%, up at 43,189.00 points (at 12:02 PM AEDT).

Reason behind the fall in YTD FY23 revenue

Healius has listed the headwinds that are currently witnessed by the health sector and the economy.

  • Shortage of staff in frontline roles.
  • Shortage of general practitioners (GP) and a fall in GP bulk billing rates.
  • Increase in the tests requested per GP referral in comparison to the historical number after a hiatus in regular testing during Covid-19. This increases coning under the Medicare Benefits Systems.

According to ASX announcement, Covid-19 testing has decreased from 13,000 tests per day in July to 3000 – 4000 in October and November. Healius said that an industry-wide fall in Covid-19 polymerase chain reaction (PCR) testing had impacted the Covid-related revenue. As reported, the Covid revenue dropped by 85.4%. To handle this demand shift, the company is adjusting its cost base.

Imaging revenue grew by 8.6% on pcp, and Healius said it is growing faster in November. The company said that growth in Imaging revenue is above-market, driven by investment in consumer-facing digital services and public hospital contract wins.

Sustainable Improvement Program (SIP) of Healius

In FY22, the company reported significant progress in its SIP, such as optimising the collection entre footprint to increase margin per centre and average revenue. With the aim of reducing costs, the company re-engineered its lab processes and back office. Tools were introduced to manage labour in-line with demand.

During the annual general meeting, the company said that the company expects to exit FY23 with a target margin of 13 to 14%, under the assumption that BAU volumes continue to recover according to expectations.

Read more on Kalkine Media

Healius’ (ASX:HLS) revenue falls by 31% in YTD FY23; here’s why
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email